

Development of a Behavior Modification System Using Minimally/Non-Invasive Weekly Average Blood Glucose Monitoring for Home Use (PROVIGATE, Inc.)



○ Business Plan

Conventional self-monitoring methods for blood glucose are highly invasive and costly, which prevents most diabetic patients from performing adequate self-monitoring. To address this issue, this project focuses on glycated albumin (GA) as a weekly average blood glucose marker. Our aim is to demonstrate the feasibility of mass-producing a minimally/non-invasive, cost-effective home blood glucose monitoring system, ultimately realizing a business with projected annual revenue of 500 billion yen and a corporate value of 5 trillion yen.

○ Research Outline

Non-Disclosure

City	Year of Establishment	Founder
Bunkyo-ku, Tokyo	2015	Koshin Sekimizu

Partner VC	Latest round of Fundraising	Valuation
-	Series C	Non-Disclosure

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
HealthCare	DMP 2024～2026FY	JPY 1,199 million	United States

○ International collaborative technology demonstration

- Contract with local partners
- Relationship development with potential local partner

We will investigate whether weekly GA monitoring combined with an app and telemedicine can effectively drive behavioral changes and improve blood glucose levels in the United States, similar to the Kumamoto Phase 2 clinical study in Japan, across diverse racial and cultural backgrounds. Additionally, as part of market research, we will assess diabetes-related needs in the U.S., standard treatments, and develop an insurance coverage strategy tailored to FDA requirements as well as Medicare, Medicaid, and private insurance.

Contact Information :

tel : 03-5615-8285

e-mail : info@provigat.com

Website : <https://provigat.com/en/>

As of August, 2024